BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Federal Trade Commission
Fish and Richardson
Julphar
Daiichi Sankyo
US Department of Justice
Deloitte
Fuji
Chubb
Farmers Insurance

Generated: January 19, 2018

DrugPatentWatch Database Preview

NALFON Drug Profile

« Back to Dashboard

Which patents cover Nalfon, and what generic alternatives are available?

Nalfon is a drug marketed by Xspire Pharma and Dista and is included in two NDAs.

The generic ingredient in NALFON is fenoprofen calcium. There are nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fenoprofen calcium profile page.
Drug patent expirations by year for NALFON
Pharmacology for NALFON
Medical Subject Heading (MeSH) Categories for NALFON

US Patents and Regulatory Information for NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dista NALFON fenoprofen calcium TABLET;ORAL 017710-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-004 Jul 21, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NALFON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Dista NALFON fenoprofen calcium TABLET;ORAL 017710-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
McKinsey
US Army
Federal Trade Commission
Argus Health
Fish and Richardson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot